 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
16 News |  |
- || radgocitabine (DFP-10917) - Delta / Fly Pharma
Enrollment open, Combination therapy: DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 30, 2024
P1/2, N=39, Recruiting, Sponsor: Delta-Fly Pharma, Inc.
Not yet recruiting --> Recruiting
- || radgocitabine (DFP-10917) - Delta / Fly Pharma
New P1/2 trial, Combination therapy: DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 23, 2024
P1/2, N=39, Not yet recruiting, Sponsor: Delta-Fly Pharma, Inc.
- | DFP-14927 - Delta / Fly Pharma
Preclinical, Journal: A polyethylene glycol-conjugate of deoxycytidine analog, DFP-14927, produces potential antitumor effects on pancreatic tumor-xenograft murine models via inducing G2/M arrest. (Pubmed Central) - May 22, 2023
Intravenous administration of the newly synthesized DFP-14927 has induced G2/M arrest in human pancreatic tumor-xenograft murine models, which represents an improvement in the pharmacokinetics of DFP-10917. DFP-14927 could be an alternative for patients who cannot accept prolonged or continuous infusions of DFP-10917.
- || DFP-10917 - Delta / Fly Pharma, Nippon Shinyaku
Clinical, P1/2 data, Journal: Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. (Pubmed Central) - Feb 14, 2020
DFP-10917 as a 14-day continuous intravenous infusion at a dose of 6 mg/m /day can be administered safely and appears to be effective in patients with recurrent or refractory AML. A phase 3 investigation comparing DFP-10917 monotherapy versus standard of care in an early recurrent or refractory AML setting is warranted.
- || DFP-10917 - Delta / Fly Pharma, Nippon Shinyaku
P1 data, PK/PD data, Journal: Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. (Pubmed Central) - Jan 23, 2020
Preliminary activity was suggested. Pharmacodynamic data demonstrate biological activity at the tested doses.
- | radgocitabine (DFP-10917) - Delta / Fly Pharma
Trial completion: Phase I/II Study of DFP-10917 in Patients With Acute Leukemia (clinicaltrials.gov) - Oct 24, 2019
P1/2, N=69, Completed, Sponsor: Delta-Fly Pharma, Inc.
Pharmacodynamic data demonstrate biological activity at the tested doses. Active, not recruiting --> Completed
- | radgocitabine (DFP-10917) - Delta / Fly Pharma
Enrollment open, Trial initiation date: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (clinicaltrials.gov) - Oct 21, 2019
P3, N=450, Recruiting, Sponsor: Delta-Fly Pharma, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Apr 2019 --> Nov 2019
- | DFP-10917 - Delta / Fly Pharma, Nippon Shinyaku
P2 data, Journal: Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. (Pubmed Central) - Jun 5, 2019
Conclusion Overall, single-agent DFP-10917 did not show meaningful antitumor activity in chemotherapy-refractory advanced CRC. The safety profile of DFP-10917 was tolerable and similar to that observed in earlier clinical studies.
- |||||||||| radgocitabine (DFP-10917) - Delta / Fly Pharma
New P3 trial: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (clinicaltrials.gov) - Apr 23, 2019
P3, N=450, Not yet recruiting, Sponsor: Delta-Fly Pharma, Inc.
- ||| radgocitabine (DFP-10917) - Delta / Fly Pharma
Enrollment closed, Trial primary completion date: Phase I/II Study of DFP-10917 in Patients With Acute Leukemia (clinicaltrials.gov) - Mar 3, 2017
P1/2, N=60, Active, not recruiting, Sponsor: Delta-Fly Pharma, Inc.
The safety profile of DFP-10917 was tolerable and similar to that observed in earlier clinical studies. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017
- || radgocitabine (DFP-10917) - Delta / Fly Pharma
Trial primary completion date: Phase I/II Study of DFP-10917 in Patients With Acute Leukemia (clinicaltrials.gov) - Oct 26, 2015
P1/2, N=60, Recruiting, Sponsor: Delta-Fly Pharma, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Sep 2014 --> Dec 2016
- ||||| radgocitabine (DFP-10917) - Delta / Fly Pharma
New P1/2 trial: Phase I/II Study of DFP-10917 in Patients With Acute Leukemia (clinicaltrials.gov) - Oct 3, 2012
P1/2, N=60, Recruiting, Sponsor: Delta-Fly Pharma, Inc.